Literature DB >> 6467500

The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle.

V J Harvey, M L Slevin, R C Woollard, A Johnston, M J Barnett, P F Wrigley, P Turner.   

Abstract

The oral bioavailability of methotrexate is variable and may be dose-dependent. The absorption of 'interval' oral methotrexate, which is given between cycles of chemotherapy, is unknown. The bioavailability of oral methotrexate has been studied in eight patients, acting as their own controls, to assess the effect of subdivision of the dose, the formulation, and the timing of the methotrexate within the chemotherapy cycle. The mean bioavailability for all the oral methods of administration was 28.2% +/- 3.7% compared with the same dose given IV. Absorption was uninfluenced by subdivision of the dose, liquid or tablet formulation, or administration on day 1 or day 10 of the chemotherapy cycle.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467500     DOI: 10.1007/bf00257121

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

1.  The fluorometric measurement of the absorption, distribution and excretion of single doses of 4-amino-10-methyl pteroylglutamic acid (amethopterin) in man.

Authors:  M V FREEMAN
Journal:  J Pharmacol Exp Ther       Date:  1958-01       Impact factor: 4.030

2.  Outpatient chemotherapy for breast cancer.

Authors:  R Bell; J R Sullivan; W J Moon; J Marty; J Shaw
Journal:  Br Med J       Date:  1978-04-01

3.  Effect of route of administration and effusions on methotrexate pharmacokinetics.

Authors:  S H Wan; D H Huffman; D L Azarnoff; R Stephens; B Hoogstraten
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

4.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors:  E S Henderson; R H Adamson; V T Oliverio
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

5.  STRIPE: an interactive computer program for the analysis of drug pharmacokinetics.

Authors:  A Johnston; R C Woollard
Journal:  J Pharmacol Methods       Date:  1983-05

6.  Comparison of serum concentrations of methotrexate after various routes of administration.

Authors:  M Freeman-Narrod; B J Gerstley; P F Engstrom; R S Bornstein
Journal:  Cancer       Date:  1975-11       Impact factor: 6.860

7.  Assay of therapeutic doses of methotrexate in body fluids of patients with psoriasis.

Authors:  W C Noble; P M White; H Baker
Journal:  J Invest Dermatol       Date:  1975-02       Impact factor: 8.551

8.  Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).

Authors:  A T Skarin; G P Canellos; D S Rosenthal; D C Case; J M MacIntyre; G S Pinkus; W C Moloney; E Frei
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

9.  Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia?

Authors:  C R Pinkerton; S G Welshman; J F Glasgow; J M Bridges
Journal:  Lancet       Date:  1980-11-01       Impact factor: 79.321

10.  Combination chemotherapy using high or low dose methotrexate for small cell carcinoma of the lung--a randomised trial.

Authors:  A M Arnold; C J Williams; G M Mead; R B Buchanan; J A Green; F M Macbeth; J M Whitehouse
Journal:  Med Oncol Tumor Pharmacother       Date:  1984
View more
  4 in total

1.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

Review 2.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

3.  Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid.

Authors:  M B Lilly; G A Omura
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Relative bioavailability of oral low dose methotrexate. A comparison of 2 different formulations.

Authors:  S D Fosså; K Tveit; O Börmer; A Moxnes; N P Jørgensen; H Orjaseter; D T Kristoffersen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.